Compare DexCom, Inc. (DXCM) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? DexCom, Inc. trades at $89.51 (market cap $33.79B), while Vanguard Dividend Appreciation Index Fund ETF trades at $245.74. Which is the better fit depends on your goals.
| DXCM | VIG | |
|---|---|---|
Market Cap | $33.79B | — |
Sector | Health | — |
52-Week High | $89.53 | $245.79 |
52-Week Low | $54.84 | $208.67 |
Enterprise Value | $33.24B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
VIG trades at $245.92, up 0.05% on the day, with a bullish technical bias from moving averages but overbought RSI signals. The ETF focuses on dividend growth stocks like Broadcom, offering a 1.5% yield with a 20-year dividend growth streak. Recent news highlights its role in retirement income strategies amid Social Security adjustments.
Outlook remains positive for long-term investors seeking stable dividend growth, though high RSI levels suggest near-term consolidation risks. Competition with higher-yield ETFs and market volatility pose challenges, but institutional interest and consistent methodology support resilience.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
